Kiyoshi Tachikawa

This inventor holds 27 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in RNA Therapeutics. Top assignees: Arcturus Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., University of California. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kiyoshi Tachikawa. Retrieved from https://idiyas.com/inventor/kiyoshi-tachikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 19)

% Patents Active = 96.3

CIPO Patents = 4 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 22)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 41(Granted Patents)

Company Filing History:

24 out of 65

Arcturus Therapeutics, Inc.

patents

2 out of 36

Ultragenyx Pharmaceutical Inc.

patents

1 out of 16,035

University of California

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

RNA Therapeutics

Glycogen Storage Disease

Immune Responses

Cystic Fibrosis

Hepatitis B Virus

Gene Editing

Amyloidosis

Vaccine Compositions

Nucleic Acids

Therapeutic Oligomers

Translatable Molecules

Ornithine Transcarbamylase Deficiency

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703858 - THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III (2026-08-11),

2. 12509698 - SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS (2025-12-30),

3. 12398379 - Compositions and methods for treating ornithine transcarbamylase deficiency (2025-08-26),

4. 12390524 - Compositions and methods for inducing immune responses (2025-08-19),

5. 12351834 - Compositions and methods for the treatment of ornithine transcarbamylase deficiency (2025-07-08),

6. 12290567 - Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates (2025-05-06),

7. 12220455 - Coronavirus vaccine compositions and methods (2025-02-11),

8. 12070509 - Nucleic acids and methods of treatment for cystic fibrosis (2024-08-27),

9. 11939600 - Compositions and methods for treating phenylketonuria (2024-03-26),

10. 11939363 - Translatable molecules and synthesis thereof (2024-03-26),

11. 11759515 - Compositions and methods for inducing immune responses (2023-09-19),

12. 11744887 - Coronavirus vaccine compositions and methods (2023-09-05),

13. 11685921 - Molecules and agents for treating hepatitis B virus (2023-06-27),

14. 11685906 - Compositions and methods for treating ornithine transcarbamylase deficiency (2023-06-27),

15. 11407800 - Translatable molecules and synthesis thereof (2022-08-09),

Title: Kiyoshi Tachikawa: Innovator in Biotechnology

Introduction: Kiyoshi Tachikawa is a prominent inventor based in San Diego, California, known for his significant contributions to the field of biotechnology. With 21 patents to his name, Tachikawa has been instrumental in developing innovative solutions to address pressing health challenges, particularly in the areas of viral infections and genetic disorders.

Latest Patents: Among his groundbreaking patents are compositions and methods for a coronavirus vaccine that include nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins. These developments aim to induce robust immune responses, facilitating the fight against the ongoing pandemic. Additionally, Tachikawa's work on cystic fibrosis is noteworthy, with patents describing nucleotides that encode the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. His research includes mRNA constructs designed for in vitro and in vivo expression of CFTR protein, which can be delivered via lipids to treat cystic fibrosis through inhalation.

Career Highlights: Kiyoshi Tachikawa has made significant strides while working at leading biotechnology firms such as Arcturus Therapeutics and Ultragenyx Pharmaceutical. His expertise and innovative approaches have helped these companies in their missions to develop life-changing therapies and vaccines.

Collaborations: Throughout his career, Tachikawa has collaborated with notable colleagues, including Padmanabh Chivukula and Joseph E. Payne. These partnerships exemplify the collaborative spirit often found in the field of research and development, fostering innovation and ensuring the advancement of biotechnological solutions.

Conclusion: Kiyoshi Tachikawa's contributions to biotechnology through his numerous patents and collaborations highlight his role as a key innovator. His work in developing therapies for infectious diseases and genetic disorders continues to pave the way for future advancements in healthcare. As a respected inventor in San Diego, Tachikawa's ongoing research promises to have a lasting impact in the field of medicine.

Profile summary based on public USPTO records.